|
Patent landscape, scope, and claims: |
United States Drug Patent 4,175,128: Scope, Claims, and Landscape Analysis
What is United States Drug Patent 4,175,128?
United States Drug Patent 4,175,128, titled "Process for preparing crystalline steroid derivatives," was granted on November 18, 1979. The patent describes a method for producing a specific crystalline form of betamethasone, a potent synthetic corticosteroid. The claimed process aims to yield a stable, easily handled crystalline product with improved properties compared to previously available forms. The patent assignee is Schering Corporation [1].
What Does the Patent Claim?
The core of United States Patent 4,175,128 lies in its claims, which define the legal boundaries of the invention. Claim 1, the independent claim, is central to understanding the patent's scope.
Claim 1: "A process for preparing a crystalline form of 17,21-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione which comprises treating a solution of 17,21-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione in a mixed solvent system of from 20 to 40% by volume of an alcohol and from 60 to 80% by volume of water with from 0.01 to 0.1 mol per 100 g of the steroid of an alkali metal hydroxide, thereafter introducing seed crystals of the desired crystalline form and continuing agitation until crystallization is complete." [1]
This claim details several key aspects of the process:
- Active Pharmaceutical Ingredient (API): The patent focuses on the production of 17,21-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione, which is betamethasone.
- Crystalline Form: The objective is to obtain a specific crystalline form of betamethasone.
- Solvent System: The process uses a mixed solvent system comprising an alcohol (20-40% by volume) and water (60-80% by volume). The specific alcohol is not explicitly defined in claim 1 but is implied to be a common, water-miscible alcohol in pharmaceutical manufacturing.
- Alkali Metal Hydroxide Treatment: A crucial step involves treating the steroid solution with an alkali metal hydroxide, specifically 0.01 to 0.1 mol per 100 g of steroid. This likely facilitates the crystallization process or controls crystal morphology.
- Seeding and Agitation: The introduction of seed crystals of the desired crystalline form and subsequent agitation are essential for initiating and completing the crystallization process.
Dependent claims further refine the process by specifying particular alcohols, temperatures, and concentrations. For instance, dependent claims might specify methanol or ethanol as the alcohol component or define a particular temperature range for the crystallization.
What is the Scope of the Patent?
The scope of United States Patent 4,175,128 is narrowly defined by its claims. It covers a specific method of producing a particular crystalline form of betamethasone. This means that any entity wishing to practice this exact process for manufacturing crystalline betamethasone in the United States would likely require a license from the patent holder.
The patent does not cover:
- Other crystalline forms of betamethasone.
- Different synthetic routes to betamethasone.
- The therapeutic uses of betamethasone.
- Formulations containing betamethasone unless they are directly tied to the claimed manufacturing process.
However, the patent's implications extend to the pharmaceutical industry by providing a route to a specific, improved form of a widely used corticosteroid. This can impact generic manufacturers, formulators, and any company involved in the production or supply chain of betamethasone.
What is the Patent Landscape for Betamethasone?
The patent landscape for betamethasone is extensive, reflecting its long history and therapeutic importance. While United States Patent 4,175,128 pertains to a specific manufacturing process, numerous other patents exist covering:
- Composition of Matter Patents: These are typically the earliest and broadest patents, covering the active molecule itself. For betamethasone, these foundational patents have long expired.
- Formulation Patents: These patents cover specific drug products, such as creams, ointages, solutions, or injectable suspensions, that enhance delivery, stability, or efficacy. Examples include formulations for topical application or ophthalmic use.
- Method of Use Patents: These patents claim specific therapeutic applications of betamethasone for treating particular diseases or conditions.
- Polymorph Patents: While 4,175,128 claims a "crystalline form," subsequent patents may claim other novel crystalline forms (polymorphs) with distinct physical properties like solubility, stability, or bioavailability.
- Manufacturing Process Patents: Like 4,175,128, these patents cover novel or improved methods for synthesizing or purifying betamethasone or its intermediates.
Key Players in the Betamethasone Market and their Patent Activity:
Several pharmaceutical companies have been active in the betamethasone space, including original innovators and generic manufacturers.
- Original Innovators (e.g., Schering Corporation): Historically held key composition of matter and early process patents. Schering Corporation, now part of Merck & Co., was the assignee of 4,175,128.
- Generic Manufacturers (e.g., Teva Pharmaceuticals, Mylan/Viatris, Sun Pharmaceutical Industries): These companies focus on developing bioequivalent versions of off-patent drugs. Their patent strategies often involve developing non-infringing manufacturing processes, new formulations, or combinations with other active ingredients.
- Specialty Pharmaceutical Companies: Companies developing advanced drug delivery systems or niche applications of betamethasone.
Challenges in the Betamethasone Patent Landscape:
- Patent Thickets: For widely used drugs, a complex web of patents can emerge, making it difficult for new entrants to navigate without infringing existing rights.
- Evergreening: Strategies to extend patent protection beyond the original term, often through new formulations or delivery methods.
- ANDA Litigation: Generic companies challenging the validity or infringement of patents held by brand-name manufacturers during the Abbreviated New Drug Application (ANDA) process.
The expiration of foundational composition of matter patents has led to a highly competitive generic market for betamethasone. However, patents like 4,175,128, covering specific manufacturing processes or crystalline forms, can still provide a competitive advantage or create barriers to entry for generic manufacturers who must devise non-infringing routes.
What are the Implications of Patent 4,175,128 for R&D and Investment?
United States Patent 4,175,128, despite its age, has several implications for research and development (R&D) and investment decisions within the pharmaceutical sector.
For R&D:
- Process Development: Companies developing generic betamethasone active pharmaceutical ingredients (APIs) must carefully analyze the claims of 4,175,128 to ensure their manufacturing processes do not infringe. This may necessitate developing alternative crystallization methods or solvent systems.
- Polymorph Research: The patent claims a specific "crystalline form." Further research into other potential crystalline forms (polymorphs) of betamethasone could lead to new patentable inventions with superior properties. Understanding the specific characteristics of the form produced by the patented process is crucial.
- Impurity Profiling: The patented process might lead to a specific impurity profile. R&D teams need to characterize the impurities generated by their own processes and compare them to those from the patented method to avoid indirect infringement or meet regulatory standards.
- Quality by Design (QbD): For companies looking to optimize betamethasone manufacturing, understanding the parameters defined in 4,175,128 (e.g., solvent ratios, alkali concentration, seeding protocols) provides a baseline for further QbD studies aimed at process improvement and robustness.
For Investment:
- Generic Market Entry Barriers: For investors considering funding generic betamethasone API manufacturers, the existence of process patents like 4,175,128 represents a potential barrier. Companies with freedom-to-operate (FTO) or a license for such patented processes may have a competitive advantage.
- Licensing Opportunities: Companies holding patents on specific manufacturing processes may offer licensing opportunities to other pharmaceutical firms, creating revenue streams. Investors can evaluate the potential for such licensing deals.
- Risk Assessment in Acquisitions: When evaluating acquisitions of companies involved in betamethasone production, investors must conduct thorough due diligence on intellectual property, including an assessment of potential infringement risks related to existing process patents.
- Investment in Novel Formulations: Given the expiration of composition of matter patents, investment focus for betamethasone may shift towards novel formulations or combination therapies that offer patent protection and market differentiation. Understanding the established manufacturing processes helps in assessing the feasibility and cost of producing these new formulations.
- Valuation of API Suppliers: The ability of an API supplier to produce betamethasone efficiently and without infringing on established process patents is a key factor in its valuation. Investors would seek evidence of FTO or proprietary, non-infringing processes.
The specific crystalline form achieved through the process claimed in patent 4,175,128 is likely a well-established and characterized polymorph of betamethasone. Its stability, solubility, and manufacturing reproducibility would have been critical advantages at the time of patenting. Any new entrant must demonstrate that their process yields a composition that is either distinct from the patented form or manufactured through a method that does not infringe the claimed steps.
Key Takeaways
- United States Patent 4,175,128 claims a specific process for producing crystalline betamethasone using a defined solvent system, alkali hydroxide treatment, seeding, and agitation.
- The patent's scope is limited to this particular manufacturing method, not the betamethasone molecule itself or its therapeutic uses.
- The betamethasone patent landscape is crowded, with patents covering composition of matter (expired), formulations, methods of use, polymorphs, and manufacturing processes.
- Patent 4,175,128 is relevant for R&D in generic betamethasone API development, necessitating non-infringing process design.
- For investors, the patent represents a factor in assessing generic market entry barriers, licensing opportunities, and acquisition risks.
Frequently Asked Questions
-
When did United States Patent 4,175,128 expire?
United States Patent 4,175,128 expired on November 18, 1996, twenty years after its filing date or seventeen years after grant, whichever was longer, per patent term regulations at the time of grant. (Note: Specific expiration dates for older patents can be complex due to patent term adjustment provisions, but the primary term would have concluded.)
-
Does this patent prevent the sale of generic betamethasone?
No, the patent does not prevent the sale of generic betamethasone. However, it does restrict the use of the specific manufacturing process it claims for producing betamethasone. Generic manufacturers must ensure their own processes do not infringe.
-
Can a company develop a new crystalline form of betamethasone and patent it, even if 4,175,128 exists?
Yes, provided the new crystalline form is novel, non-obvious, and has utility. Patent 4,175,128 claims a specific process to obtain a specific crystalline form, not all possible crystalline forms.
-
What is the significance of the "crystalline form" mentioned in the patent?
Different crystalline forms (polymorphs) of an active pharmaceutical ingredient can exhibit variations in physical properties such as solubility, dissolution rate, stability, and manufacturability. A patented crystalline form suggests an improvement in one or more of these properties.
-
Who currently owns or licenses the rights to United States Patent 4,175,128?
The patent was originally assigned to Schering Corporation. As the patent has long expired, its rights are no longer in effect. Its historical significance lies in its contribution to the manufacturing of betamethasone during its patent term.
Citations
[1] Schering Corporation. (1979). Process for preparing crystalline steroid derivatives (U.S. Patent No. 4,175,128). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
